Todays Report: The Valeant Pharmaceuticals International Inc. (VRX) Price Target Cut to $35.00 by Analysts at Royal Bank Of Canada

The Valeant Pharmaceuticals International Inc. (VRX) Price Target Cut to $35.00 by Analysts at Royal Bank Of Canada

Valeant Pharmaceuticals International Inc. (NYSE:VRX) had its price target decreased by Royal Bank Of Canada from $36.00 to $35.00 in a report issued on Wednesday, StockTargetPrices.com reports. Royal Bank Of Canada currently has a sector perform rating on the specialty pharmaceutical company’s stock.

VRX has been the topic of several other research reports. Morgan Stanley reaffirmed a positive rating on shares of Valeant Pharmaceuticals International in a research note on Friday, August 19th. Wells Fargo & Co. reaffirmed an underperform rating and set a $19.50 target price on shares of Valeant Pharmaceuticals International in a research note on Friday, September 30th. RBC Capital Markets set a $36.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a research note on Friday, August 19th. Deutsche Bank AG started coverage on shares of Valeant Pharmaceuticals International in a research note on Tuesday, September 20th. They set a hold rating and a $30.00 target price on the stock. Finally, Jefferies Group reaffirmed a buy rating and set a $40.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Six research analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Valeant Pharmaceuticals International currently has an average rating of Hold and an average target price of $56.49.

Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.42% on Wednesday, reaching $22.14. 6,072,296 shares of the company traded hands. Valeant Pharmaceuticals International has a 1-year low of $18.55 and a 1-year high of $179.83. The stock has a 50 day moving average of $27.08 and a 200-day moving average of $26.92. The stock’s market capitalization is $7.69 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.48 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The business had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same period last year, the firm earned $2.14 EPS. The company’s revenue for the quarter was down 11.4% compared to the same quarter last year. On average, equities analysts anticipate that Valeant Pharmaceuticals International will post $6.53 EPS for the current year.

In related news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The stock was purchased at an average cost of $24.65 per share, with a total value of $98,600.00. Following the completion of the acquisition, the director now directly owns 20,726 shares in the company, valued at $510,895.90. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 16.37% of the company’s stock.

Several large investors have recently modified their holdings of the company. Paulson & CO. Inc. increased its stake in shares of Valeant Pharmaceuticals International by 44.6% in the second quarter. Paulson & CO. Inc. now owns 19,072,000 shares of the specialty pharmaceutical company’s stock valued at $384,110,000 after buying an additional 5,883,900 shares in the last quarter. FMR LLC increased its stake in shares of Valeant Pharmaceuticals International by 185.4% in the second quarter. FMR LLC now owns 15,545,539 shares of the specialty pharmaceutical company’s stock valued at $313,087,000 after buying an additional 10,099,493 shares in the last quarter. Jackson Square Partners LLC increased its stake in shares of Valeant Pharmaceuticals International by 15.0% in the first quarter. Jackson Square Partners LLC now owns 7,437,220 shares of the specialty pharmaceutical company’s stock valued at $205,390,000 after buying an additional 968,782 shares in the last quarter. Davis Selected Advisers increased its stake in shares of Valeant Pharmaceuticals International by 0.9% in the second quarter. Davis Selected Advisers now owns 7,304,762 shares of the specialty pharmaceutical company’s stock valued at $147,118,000 after buying an additional 64,425 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Valeant Pharmaceuticals International by 11.9% in the second quarter. Vanguard Group Inc. now owns 5,917,325 shares of the specialty pharmaceutical company’s stock valued at $119,175,000 after buying an additional 631,211 shares in the last quarter. 63.59% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Related posts

Leave a Comment